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Abstract 
Introduction: Stiff-person syndrome (SPS) is manifested by fluctuating rigidity of axial 
musculature with painful episodic spasms due to simultaneous co-contraction of agonist and 
antagonist muscles. We present a case report and video illustrating response to treatment 
with rituximab.  
Materials and Methods: Case description and video are provided. A literature search for 
other reports of treatment with rituximab was performed.  
Results: Nine cases in addition to our case were described. Substantial clinical benefit was 
reported in 7/9 (78%) cases. Four out of 9 (44%) cases displayed persistent anti-glutamic acid 
decarboxylase (GAD) antibody positivity.  
Conclusion: Rituximab is an important treatment strategy in SPS. The persistence of anti-
GAD antibody positivity even with clinical remission remains to be elucidated. 
 
Introduction 
Stiff-person syndrome (SPS), first described by Moersch and Woltman in 1956 [1], 
typically presents between the 3rd and 6th decade of life and is manifested by 
fluctuating rigidity of axial musculature with painful episodic simultaneous co-
contraction of agonist and antagonist muscles. Episodes may be triggered by tactile, 
emotional, or auditory stimuli. Comorbid anxiety may be present which may raise 
suspicion of a psychogenic disorder and delay diagnosis [2]. Antibodies against 
glutamic acid decarboxylase (GAD), gamma-amino butyric acid A receptor-associated 
protein, and amphiphysin I have been identified in this disorder [2, 3].  
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Case Report 
The patient is a 12-year-old right-handed Hispanic boy who presented for evaluation of painful 
axial muscle contractions and exaggerated startle response. 
His first symptom, stiffness of the right leg during ambulation, occurred at age 5. At age 7, he had a 
generalized seizure lasting 5 min with unresponsiveness and jerking movements of all extremities, 
but without tongue biting, bowel or bladder incontinence. He was controlled on levetiracetam until 
age 11. At that time, he developed episodes of nightly awakening with a prodrome of anxiety and 
tachycardia typically followed by up to 20 min of painful hyperlordotic posturing. Occasional episodes 
lasted for up to 2 h. Frequency of episodes gradually worsened from once to several times a day. 
Startle response to auditory and tactile stimuli triggered many of the episodes. In order to prevent 
falls, the patient became wheelchair bound. There is no family history of similar disorder, but there is 
consanguinity (the patient’s paternal grandmother and grandfather are second cousins). 
On examination, the patient manifested sustained right ankle clonus, markedly contracted 
thoracolumbar paraspinal muscles, hyperlordotic posture, and classic ‘board-like’ abdomen. Tactile or 
auditory stimulation triggered episodes with right lower extremity sustained myoclonus, diaphoresis, 
painful exacerbation of the hyperlordosis with thoracolumbar axial and abdominal muscle co-
contraction, and rocking movements which were likely a response to the axial contraction. 
Magnetic resonance imaging of the brain and video electroencephalography studies were normal. 
Anti-GAD antibody was positive at 4,405 nmol/l, but there were no detectable anti-amphiphysin 
antibodies. Muscle biopsy was normal. There was mild improvement with diazepam or clonazepam 
and monthly intravenous immunoglobulin treatment (IV Ig) [4]. Baclofen and gabapentin did not 
improve his symptoms. A course of rituximab, a monoclonal antibody which binds to B-lymphocyte 
CD surface antigens, consisting of two 500 mg/m2 treatments spaced 14 days apart, markedly 
reduced the frequency and severity of axial contractions, diminished startle response, and abolished 
sustained ankle clonus. Most importantly, his gait markedly improved and he is now able to ambulate 
with minimal assistance, partly because of residual phobia of falling (for online suppl. video, see 
www.karger.com/doi/10.1159/000339446). Post-treatment anti-GAD antibody levels were not 
available. 
Materials and Methods 
A Medline search for ‘stiff-person syndrome’ and ‘rituximab’ was performed. 
Results 
The initial Medline search yielded 12 articles, of which 8 were relevant case reports 
[5–12]. The details are provided in table 1. Substantial clinical benefit was reported in 
7/9 (78%) cases (1 report described monozygotic twins). In 4/9 (44%) of these cases, 
anti-GAD antibodies remained positive after treatment. 
Discussion 
This childhood case demonstrates the classic features of SPS and the remarkable 
clinical improvement with rituximab (table 1; online suppl. video). Thus, rituximab 
should be added to other treatments of SPS such as IV Ig, plasmapheresis, 
cyclophosphamide, and mycophenolate. Other antispasmodic treatments reported to be 
effective in patients with SPS include tizanidine, piracetam, phenobarbital, and local 
botulinum toxin injections [5]. 
Although a double-blind placebo-controlled trial of rituximab on 2 patients ‘did not 
support a profound benefit’ [7], experience with rituximab, based on open-label case  
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reports, has suggested that at least 2 doses of rituximab at 350–375 mg/m2/infusion 
spaced 1–2 weeks apart [5, 12] or 4 weekly infusions [9] provide clinically meaningful 
improvement in SPS symptoms. If a relapse occurs, a repeat dose 6–8 months later may 
be needed [9, 12]. 
Hence, rituximab should be considered as an effective and less expensive alternative 
in patients with SPS and other autoimmune movement disorders who fail to obtain 
adequate response to benzodiazepines and other conventional antispasmodic and 
immunologic therapies [13]. 
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Table 1. Summary of reported SPS cases treated with rituximab 
                Baker et al. [6]  41-year-old patient with full remission of SPS after a single 
dose of rituximab (375 mg/m2) followed 6 weeks later by 
4 weekly doses (375 mg/m2/infusion). She had prior 
improvement and relapse on intravenous immunoglobulin, 
mycophenolate mofetil, cyclophosphamide, and intrathecal 
hydrocortisone treatment 
  Anti-GAD serum antibodies 
positive but decreased due to 
prior treatment regimens. 
Cerebrospinal fluid anti-GAD 
antibodies initially positive and 
disappeared 17 days after 
initiation of rituximab treatment 
                Lobo et al. [5]  41-year-old SPS patient with full remission after second 
infusion of rituximab, 15 days after first one. Dose: 375 
mg/m2/infusion 
  Anti-GAD antibodies continued to 
rise with treatment 
                Venhoff et al. [7]  Double-blind placebo-controlled trial of 34-year-old male 
monozygotic twins with SPS and autoimmune thyroiditis 
‘did not support a profound benefit’, but authors concede 
that ‘rituximab may have prevented a more severe disease 
course’ 
  Anti-GAD IgG antibody decreased 
at the same time from 205 to 103 
units/ml in both the 
placebo/rituximab and 
rituximab/placebo arms 
                Bacorro and Tehrani [8]  62-year-old man with diabetes mellitus and SPS achieved 
clinical remission with 2 doses of rituximab that were 
1 week apart 
  Anti-GAD levels remained 
elevated 
                Dupond et al. [9]  53-year-old man with SPS and positive anti-GAD and anti-
amphiphysin antibodies who had partial improvement and 
then relapse after thymectomy, prednisone, intravenous 
immunoglobulin, and mycophenolate mofetil. Rituximab 
was administered at a dose of 350 mg/m2 per week, for 
4 weeks. Symptoms reappeared after 8 months and were 
abolished after a second dose of rituximab 
  Serum anti-amphiphysin 
antibodies became undetectable. 
Anti-GAD antibodies remained 
strongly positive 
                Qureshi and Hennesy [10]  56-year-old man with diabetes mellitus and a 5-year 
history of progressive stiffness and painful spasms of his 
limbs and axial region successfully treated with 4 doses of 
rituximab over 3 months 
  Anti-GAD titers at 400 U/ml one 
year after treatment 
                Katoh et al. [11]  66-year-old woman with diabetes mellitus with clinical 
improvement of thyroid ophthalmopathy and SPS with 
3 doses of rituximab treatment 
  Anti-GAD antibodies profoundly 
decreased 2 months after 
initiation of treatment 
                Sevy et al. [12]  50-year-old woman with axial and limb spasms triggered 
by anxiety or startle response to noise. She was treated 
with 1,000 mg of rituximab in 2 injections 15 days apart. 
She had a relapse after 6 months, treated with a third 
1,000-mg rituximab injection 
  Anti-GAD serum antibodies 
increased after treatment from 
51 to 75 U/ml 
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